mRNA Vaccines and Therapeutics Market Expected to Reach USD 253.83 Billion By 2034, With 16.7% CAGR From 2025 to 2034 | PMR
December 26, 2024 02:00 ET
|
Polaris Market Research & Consulting LLP
New York, USA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Market Overview The market for mRNA vaccines and therapeutics is poised to grow, according to the latest research study by Polaris Market Research....
GEn1E Lifesciences appoints François Nader, MD as Chair of its Board of Directors
December 11, 2024 07:01 ET
|
GEn1E Lifesciences Inc.
Dr. Nader, current Independent Board Director at Moderna and Senior Advisor at Blackstone Life Sciences, joins GEn1E Lifesciences board as chair.
2024 BioTech Breakthrough Awards Program Celebrates Groundbreaking Biotechnology Innovators Around the World
November 19, 2024 08:00 ET
|
BioTech Breakthrough
LOS ANGELES, Nov. 19, 2024 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology...
Global Allergy Diagnostics and Therapeutics Market Size/Share Worth USD 78,036.1 Million by 2033 at a 8.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
November 18, 2024 12:30 ET
|
Custom Market Insights
Austin, TX, USA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Allergy Diagnostics and Therapeutics Market Size, Trends and Insights By Product...
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
November 14, 2024 07:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007, in Patients with Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia or T Cell Lymphoblastic Lymphoma
November 12, 2024 07:00 ET
|
Wugen
Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007
Tourmaline Bio to Present at Upcoming Investor Conferences
October 31, 2024 07:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio to Present at Upcoming Investor Conferences
A Race Against Blindness Grants $1 Million Supporting Axovia Therapeutics’ Planned Clinical Trial for Bardet-Biedl Syndrome (BBS)
October 30, 2024 08:01 ET
|
A Race Against Blindness
A Race Against Blindness grants $1M to Axovia Therapeutics for a clinical trial targeting blindness and obesity in Bardet-Biedl Syndrome.
A Family’s Race To Treat Childhood Blindness: A Race Against Blindness Grants $1 Million to Bardet-Biedl Syndrome Research
October 30, 2024 08:00 ET
|
A Race Against Blindness
Arizona Family’s Journey: A Race Against Blindness grants $1M to Bardet-Biedl Syndrome research, fueling hope and potential cures for childhood blindness.
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
October 15, 2024 07:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November